Kenvue on Thursday forecast that its annual profit would be flat year-over-year as the consumer health firm anticipates a ...

Shares of Kenvue rose in early Thursday trading after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter ...

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new ...

The leadership change comes at the end of a week in which the California-based toymaker landed squarely in the crosshairs of ...

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

(Reuters) -Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday, as strong demand for its self ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

(Reuters) -Kenvue beat quarterly profit and revenue estimates on Thursday as better-than-expected demand for cough-and-cold ...

Shares of Kenvue Inc. KVUE slid 1.80% to $24.00 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 3.26% to 5,844.19 and the ...

Kenvue Inc. has announced the appointment of Amit Banati as chief financial officer, effective today. He will be responsible ...

Kenvue (KVUE) delivered earnings and revenue surprises of 9.09% and 1.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

The Neutrogena and Aveeno owner has also increased its 2025 full-year outlook to reflect the impact of costs associated with ...